Wednesday, 7 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Bliss GVS Pharma Ltd

NSE: BLISSGVS · BSE: 506197 · Pharmaceuticals & Biotechnology · 40 announcements

Share price
₹685.00
Market cap
₹7,284 Cr
Revenue (annual)
₹927.1 Cr
Net profit (annual)
₹129.1 Cr
P/E (TTM)
53.5×Sector 47.4×
Promoter holding
35.01%-0.35% QoQ
FII holding
8.07%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

19:48 IST BSE
Management Change

Bliss GVS Pharma Management Change

Bliss GVS Pharma Ltd announced the resignation of Mr. Sachin Saboo, General Manager – Regulatory & Clinical, effective from the close of business hours on July 24, 2026.

18:50 IST BSE
Management Change

Bliss GVS Pharma Management Change

Bliss GVS Pharma appointed Rahul Adakmol as CEO, effective July 15, 2026. Narsimha Shibroor Kamath stepped down as CEO but remains Managing Director.

18:57 IST NSE
Management Change

Bliss GVS Pharma Management Change

Mr. Santosh Parab completed his final term as Independent Director on May 25, 2026. This planned leadership change follows statutory term limits for independent directors.

18:38 IST NSE
Management Change

Bliss GVS Pharma Management Change

Bliss GVS Pharma Limited has appointed Mr. Vijayanarayanan Mahadevan and Mr. Deepak Rameshchandra Shah as Additional Independent Directors for five-year terms effective April 03, 2026. Both appointees are seasoned finance professionals and Chartered Accountants. The appointments are subject to shareholder approval via postal ballot.

Execution
5 years